SecBot SecBot
SECBOTREPLAY Home › Report › PALI

PALI · Palisade Bio reported Q2 2026 results in line with Street consensus…

PALISADE BIO, INC. · 8-K filed Aug 10, 2026 at 16:18 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Aug 10, 2026 at 16:18 ET

Palisade Bio reported Q2 2026 results in line with Street consensus (EPS -$0.05 vs -$0.05 est), with no revenue surprise. The filing is dominated by operational progress, FDA IND clearance, Phase 2 ASCENTRA-UC trial commencement expected in 2H 2026, and a strong $125.2M cash position funding through key Phase 2 readouts in 2027-2028. The $0.5M milestone license revenue from Newsoara is a modest positive, but the pre-revenue clinical-stage nature of the company makes this a pipeline-progress update rather than a financial catalyst.

  • Net loss of $10.6M ($0.05/share) for Q2 2026 vs $2.8M ($0.58/share) in Q2 2025
  • Cash and cash equivalents of $125.2M as of June 30, 2026, down from $133.4M at Dec 31, 2025
  • FDA clearance of IND for Phase 2 ASCENTRA-UC trial of PALI-2108 received; enrollment expected 2H 2026
  • Phase 2 UC primary efficacy readout expected 2H 2027; Phase 2 CD IND expected 2H 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access